By Karen Roman
March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma.
The test will take place at leading cancer centers across the country, with the first patient dosed at The University of Texas MD Anderson Cancer Center, the company stated.
The MB-105 program was granted FDA orphan drug designation in January 2025 and is also in development for other CD5+ cancers, it said.
“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” said Sarah Hein, March Biosciences co-founder and CEO.
Contact:
